Latest Pharma Insights
Another FDA Alert For Abiomed As J&J Defends Safety Record
The FDA issued a safety alert on some Abiomed Impella units on May 27, closely following a May 21 alert on Automated Impella Controller (AIC) units. The company says the recall surge is tied to its rigorous compliance standards.
Medtech Insight - May 27, 2026
The FDA issued a safety alert on some Abiomed Impella units on May 27, closely following a May 21 alert on Automated Impella Controller (AIC) units. The company says the recall surge is tied to its rigorous compliance standards.
Medtech Insight - May 27, 2026
Apogee Doubles Its Cash Position As It Reports New Phase II Zumilokibart Data
Apogee signed a funding deal with Blackstone for up to $1.3bn as it reported competitive skin and itch benefits for its infrequently dosed IL-13 inhibitor zumilokibart in Part B of a Phase II study.
Scrip - May 27, 2026
Apogee signed a funding deal with Blackstone for up to $1.3bn as it reported competitive skin and itch benefits for its infrequently dosed IL-13 inhibitor zumilokibart in Part B of a Phase II study.
Scrip - May 27, 2026
PCPC Warns Administration Against New Tariffs Under Section 301
With at least 42% of cosmetic ingredients in products sold in the US unable to be sourced domestically, the Office of the US Trade Representative’s 301 investigation could have an outsize impact on the cosmetics industry.
HBW Insight - May 27, 2026
With at least 42% of cosmetic ingredients in products sold in the US unable to be sourced domestically, the Office of the US Trade Representative’s 301 investigation could have an outsize impact on the cosmetics industry.
HBW Insight - May 27, 2026
EASL Data Strengthen Case For MASH Drugs, But Bigger Trials To Come
Altimmune and D&D fight for position in the GLP-1/glucagon analog space while Madrigal’s presentations at EASL are intended to shore up Rezdiffra’s position as a foundational therapy.
Scrip - May 27, 2026
Altimmune and D&D fight for position in the GLP-1/glucagon analog space while Madrigal’s presentations at EASL are intended to shore up Rezdiffra’s position as a foundational therapy.
Scrip - May 27, 2026
Daphne Koller’s Case For A Different Kind Of AI Biotech
The insitro founder and CEO has spent eight years proving that artificial intelligence can find what human intuition cannot. Now, with the clinic finally in sight, the hardest part is just beginning.
In Vivo - May 27, 2026
The insitro founder and CEO has spent eight years proving that artificial intelligence can find what human intuition cannot. Now, with the clinic finally in sight, the hardest part is just beginning.
In Vivo - May 27, 2026
DePuy Synthes Strikes Deal For Miniature RF Tracking Tech, Aims To Ditch Line-Of-Sight Limits Across
DePuy Synthes acquires rights to MinMaxMedical's Gemtrack RF tracking technology, aiming to eliminate line-of-sight dependency across its hip, knee and shoulder robotics and navigation portfolio.
Medtech Insight - May 27, 2026
DePuy Synthes acquires rights to MinMaxMedical's Gemtrack RF tracking technology, aiming to eliminate line-of-sight dependency across its hip, knee and shoulder robotics and navigation portfolio.
Medtech Insight - May 27, 2026
Dexcom Says Stolen G7 Sensors Were Sold To Patients
CGM products that failed quality control were stolen by a third party during the scrapping process.
Medtech Insight - May 27, 2026
CGM products that failed quality control were stolen by a third party during the scrapping process.
Medtech Insight - May 27, 2026
Novartis Points To Inflections In Neuroscience
The Swiss giant has highlighted a trio of key readouts coming in the second half of the year and reiterated its commitment to gene therapy.
Scrip - May 27, 2026
The Swiss giant has highlighted a trio of key readouts coming in the second half of the year and reiterated its commitment to gene therapy.
Scrip - May 27, 2026
Particulate Matter In Fluid Path Prompts Class I Recall Of Medline Namic Manifolds
Medline says certain Namic Manifolds used in cardiac procedures should be pulled from distribution and clinical use. The company issued the recall after identifying particulates that could enter the bloodstream, resulting in serious injury or death.
Medtech Insight - May 27, 2026
Medline says certain Namic Manifolds used in cardiac procedures should be pulled from distribution and clinical use. The company issued the recall after identifying particulates that could enter the bloodstream, resulting in serious injury or death.
Medtech Insight - May 27, 2026
EU HTA Group Explains What Stays Confidential In Dossiers Undergoing Joint Clinical Assessments
Information that would be considered commercially confidential in dossiers companies submit for JCAs is discussed in a document from the Member State Coordination Group On Health Technology Assessment.
Medtech Insight - May 27, 2026
Information that would be considered commercially confidential in dossiers companies submit for JCAs is discussed in a document from the Member State Coordination Group On Health Technology Assessment.
Medtech Insight - May 27, 2026
Avista Increases CHC Investment With Germany’s Sanotact
Avista attracted to Sanotact’s “established and innovative” vitamins, minerals, and supplements platform, which spans product development, manufacturing and commercialization.
HBW Insight - May 27, 2026
Avista attracted to Sanotact’s “established and innovative” vitamins, minerals, and supplements platform, which spans product development, manufacturing and commercialization.
HBW Insight - May 27, 2026
Sandoz Escalates Chinese Antibiotics Concerns With Complaint To European Commission
Sandoz has submitted a formal complaint to the European Commission urging swift protective action over Chinese price-dumping of antibiotics, which the firm believes poses an existential threat to Europe’s own antibiotics capabilities.
Generics Bulletin - May 27, 2026
Sandoz has submitted a formal complaint to the European Commission urging swift protective action over Chinese price-dumping of antibiotics, which the firm believes poses an existential threat to Europe’s own antibiotics capabilities.
Generics Bulletin - May 27, 2026
Lupin Basks In Chinese Milestone
Lupin’s first China product approval gives it a commercial foothold in the market, while recent partnerships, record financial results and a growing complex pipeline strengthen its wider international growth ambitions.
Generics Bulletin - May 27, 2026
Lupin’s first China product approval gives it a commercial foothold in the market, while recent partnerships, record financial results and a growing complex pipeline strengthen its wider international growth ambitions.
Generics Bulletin - May 27, 2026
Ozempic Patent Expiry Sparks Brazil’s Semaglutide Gold Rush
Brazil’s approval of EMS’s Ozivy gives the country an early role in post-patent semaglutide competition, opening a synthetic follow-on route that could reshape pricing, access and Novo Nordisk’s dominance.
Generics Bulletin - May 27, 2026
Brazil’s approval of EMS’s Ozivy gives the country an early role in post-patent semaglutide competition, opening a synthetic follow-on route that could reshape pricing, access and Novo Nordisk’s dominance.
Generics Bulletin - May 27, 2026
Nuclidium Increases Series B To Fund Faster, Cheaper Radiopharmaceuticals
Switzerland-based company is pioneering use of copper-based radiopharmaceuticals, and has plans to enter Phase I this year.
Scrip - May 27, 2026
Switzerland-based company is pioneering use of copper-based radiopharmaceuticals, and has plans to enter Phase I this year.
Scrip - May 27, 2026
Aurobindo: US Govt Shutdown Delayed Lannett Deal Closure; $2bn Is FY27 US Target
Aurobindo’s acquisition of Lannett was delayed due to a partial shutdown of the US government in early 2026 but is back on track now. Meanwhile, a $2bn revenue target has been set for the US in FY27 amid plans to beat a “slugfest” in the biosimilars market.
Generics Bulletin - May 27, 2026
Aurobindo’s acquisition of Lannett was delayed due to a partial shutdown of the US government in early 2026 but is back on track now. Meanwhile, a $2bn revenue target has been set for the US in FY27 amid plans to beat a “slugfest” in the biosimilars market.
Generics Bulletin - May 27, 2026
Hengrui/Kailera’s GLP-1 Pill Proves Class-Competitive In China Phase III Diabetes Trial
Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.
Scrip - May 27, 2026
Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.
Scrip - May 27, 2026
Polpharma Biologics Secures LATAM Autoimmune Biosimilar Market With A Tuteur Deal
The deal for an undisclosed biosimilar with Argentina-based Tuteur gives Polpharma Biologics regional commercial coverage across most of Latin America.
Generics Bulletin - May 27, 2026
The deal for an undisclosed biosimilar with Argentina-based Tuteur gives Polpharma Biologics regional commercial coverage across most of Latin America.
Generics Bulletin - May 27, 2026
Astellas To Drive Strategic Brands, Pivotal Studies To Fill Xtandi Gap
Astellas has not disclosed a sales target under its new mid-term plan, but aims to mitigate Xtandi’s patent cliff with growth for existing products and the launch of late-stage candidates, while cutting costs.
Scrip - May 27, 2026
Astellas has not disclosed a sales target under its new mid-term plan, but aims to mitigate Xtandi’s patent cliff with growth for existing products and the launch of late-stage candidates, while cutting costs.
Scrip - May 27, 2026
Roche Adds Liver Disease Panel To Navify, Covering Full CLD Care Pathway From Fibrosis to Cancer
Roche has added a certified liver disease algorithm suite to its navify platform — the latest piece of a digital diagnostics strategy that now spans 130+ solutions across oncology, cardiology, nephrology, and liver disease.
Medtech Insight - May 27, 2026
Roche has added a certified liver disease algorithm suite to its navify platform — the latest piece of a digital diagnostics strategy that now spans 130+ solutions across oncology, cardiology, nephrology, and liver disease.
Medtech Insight - May 27, 2026
Mercury Rises As US Skin-Lightening Concern
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026
Apogee Doubles Its Cash Position As It Reports New Phase II Zumilokibart Data
Apogee signed a funding deal with Blackstone for up to $1.3bn as it reported competitive skin and itch benefits for its infrequently dosed IL-13 inhibitor zumilokibart in Part B of a Phase II study.
Scrip - May 27, 2026
Apogee signed a funding deal with Blackstone for up to $1.3bn as it reported competitive skin and itch benefits for its infrequently dosed IL-13 inhibitor zumilokibart in Part B of a Phase II study.
Scrip - May 27, 2026
EASL Data Strengthen Case For MASH Drugs, But Bigger Trials To Come
Altimmune and D&D fight for position in the GLP-1/glucagon analog space while Madrigal’s presentations at EASL are intended to shore up Rezdiffra’s position as a foundational therapy.
Scrip - May 27, 2026
Altimmune and D&D fight for position in the GLP-1/glucagon analog space while Madrigal’s presentations at EASL are intended to shore up Rezdiffra’s position as a foundational therapy.
Scrip - May 27, 2026
Novartis Points To Inflections In Neuroscience
The Swiss giant has highlighted a trio of key readouts coming in the second half of the year and reiterated its commitment to gene therapy.
Scrip - May 27, 2026
The Swiss giant has highlighted a trio of key readouts coming in the second half of the year and reiterated its commitment to gene therapy.
Scrip - May 27, 2026
Nuclidium Increases Series B To Fund Faster, Cheaper Radiopharmaceuticals
Switzerland-based company is pioneering use of copper-based radiopharmaceuticals, and has plans to enter Phase I this year.
Scrip - May 27, 2026
Switzerland-based company is pioneering use of copper-based radiopharmaceuticals, and has plans to enter Phase I this year.
Scrip - May 27, 2026
Hengrui/Kailera’s GLP-1 Pill Proves Class-Competitive In China Phase III Diabetes Trial
Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.
Scrip - May 27, 2026
Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.
Scrip - May 27, 2026
Astellas To Drive Strategic Brands, Pivotal Studies To Fill Xtandi Gap
Astellas has not disclosed a sales target under its new mid-term plan, but aims to mitigate Xtandi’s patent cliff with growth for existing products and the launch of late-stage candidates, while cutting costs.
Scrip - May 27, 2026
Astellas has not disclosed a sales target under its new mid-term plan, but aims to mitigate Xtandi’s patent cliff with growth for existing products and the launch of late-stage candidates, while cutting costs.
Scrip - May 27, 2026
Another FDA Alert For Abiomed As J&J Defends Safety Record
The FDA issued a safety alert on some Abiomed Impella units on May 27, closely following a May 21 alert on Automated Impella Controller (AIC) units. The company says the recall surge is tied to its rigorous compliance standards.
Medtech Insight - May 27, 2026
The FDA issued a safety alert on some Abiomed Impella units on May 27, closely following a May 21 alert on Automated Impella Controller (AIC) units. The company says the recall surge is tied to its rigorous compliance standards.
Medtech Insight - May 27, 2026
DePuy Synthes Strikes Deal For Miniature RF Tracking Tech, Aims To Ditch Line-Of-Sight Limits Across
DePuy Synthes acquires rights to MinMaxMedical's Gemtrack RF tracking technology, aiming to eliminate line-of-sight dependency across its hip, knee and shoulder robotics and navigation portfolio.
Medtech Insight - May 27, 2026
DePuy Synthes acquires rights to MinMaxMedical's Gemtrack RF tracking technology, aiming to eliminate line-of-sight dependency across its hip, knee and shoulder robotics and navigation portfolio.
Medtech Insight - May 27, 2026
Dexcom Says Stolen G7 Sensors Were Sold To Patients
CGM products that failed quality control were stolen by a third party during the scrapping process.
Medtech Insight - May 27, 2026
CGM products that failed quality control were stolen by a third party during the scrapping process.
Medtech Insight - May 27, 2026
Particulate Matter In Fluid Path Prompts Class I Recall Of Medline Namic Manifolds
Medline says certain Namic Manifolds used in cardiac procedures should be pulled from distribution and clinical use. The company issued the recall after identifying particulates that could enter the bloodstream, resulting in serious injury or death.
Medtech Insight - May 27, 2026
Medline says certain Namic Manifolds used in cardiac procedures should be pulled from distribution and clinical use. The company issued the recall after identifying particulates that could enter the bloodstream, resulting in serious injury or death.
Medtech Insight - May 27, 2026
EU HTA Group Explains What Stays Confidential In Dossiers Undergoing Joint Clinical Assessments
Information that would be considered commercially confidential in dossiers companies submit for JCAs is discussed in a document from the Member State Coordination Group On Health Technology Assessment.
Medtech Insight - May 27, 2026
Information that would be considered commercially confidential in dossiers companies submit for JCAs is discussed in a document from the Member State Coordination Group On Health Technology Assessment.
Medtech Insight - May 27, 2026
Roche Adds Liver Disease Panel To Navify, Covering Full CLD Care Pathway From Fibrosis to Cancer
Roche has added a certified liver disease algorithm suite to its navify platform — the latest piece of a digital diagnostics strategy that now spans 130+ solutions across oncology, cardiology, nephrology, and liver disease.
Medtech Insight - May 27, 2026
Roche has added a certified liver disease algorithm suite to its navify platform — the latest piece of a digital diagnostics strategy that now spans 130+ solutions across oncology, cardiology, nephrology, and liver disease.
Medtech Insight - May 27, 2026
PCPC Warns Administration Against New Tariffs Under Section 301
With at least 42% of cosmetic ingredients in products sold in the US unable to be sourced domestically, the Office of the US Trade Representative’s 301 investigation could have an outsize impact on the cosmetics industry.
HBW Insight - May 27, 2026
With at least 42% of cosmetic ingredients in products sold in the US unable to be sourced domestically, the Office of the US Trade Representative’s 301 investigation could have an outsize impact on the cosmetics industry.
HBW Insight - May 27, 2026
Avista Increases CHC Investment With Germany’s Sanotact
Avista attracted to Sanotact’s “established and innovative” vitamins, minerals, and supplements platform, which spans product development, manufacturing and commercialization.
HBW Insight - May 27, 2026
Avista attracted to Sanotact’s “established and innovative” vitamins, minerals, and supplements platform, which spans product development, manufacturing and commercialization.
HBW Insight - May 27, 2026
Mercury Rises As US Skin-Lightening Concern
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026
Sandoz Escalates Chinese Antibiotics Concerns With Complaint To European Commission
Sandoz has submitted a formal complaint to the European Commission urging swift protective action over Chinese price-dumping of antibiotics, which the firm believes poses an existential threat to Europe’s own antibiotics capabilities.
Generics Bulletin - May 27, 2026
Sandoz has submitted a formal complaint to the European Commission urging swift protective action over Chinese price-dumping of antibiotics, which the firm believes poses an existential threat to Europe’s own antibiotics capabilities.
Generics Bulletin - May 27, 2026
Lupin Basks In Chinese Milestone
Lupin’s first China product approval gives it a commercial foothold in the market, while recent partnerships, record financial results and a growing complex pipeline strengthen its wider international growth ambitions.
Generics Bulletin - May 27, 2026
Lupin’s first China product approval gives it a commercial foothold in the market, while recent partnerships, record financial results and a growing complex pipeline strengthen its wider international growth ambitions.
Generics Bulletin - May 27, 2026
Ozempic Patent Expiry Sparks Brazil’s Semaglutide Gold Rush
Brazil’s approval of EMS’s Ozivy gives the country an early role in post-patent semaglutide competition, opening a synthetic follow-on route that could reshape pricing, access and Novo Nordisk’s dominance.
Generics Bulletin - May 27, 2026
Brazil’s approval of EMS’s Ozivy gives the country an early role in post-patent semaglutide competition, opening a synthetic follow-on route that could reshape pricing, access and Novo Nordisk’s dominance.
Generics Bulletin - May 27, 2026
Aurobindo: US Govt Shutdown Delayed Lannett Deal Closure; $2bn Is FY27 US Target
Aurobindo’s acquisition of Lannett was delayed due to a partial shutdown of the US government in early 2026 but is back on track now. Meanwhile, a $2bn revenue target has been set for the US in FY27 amid plans to beat a “slugfest” in the biosimilars market.
Generics Bulletin - May 27, 2026
Aurobindo’s acquisition of Lannett was delayed due to a partial shutdown of the US government in early 2026 but is back on track now. Meanwhile, a $2bn revenue target has been set for the US in FY27 amid plans to beat a “slugfest” in the biosimilars market.
Generics Bulletin - May 27, 2026
Polpharma Biologics Secures LATAM Autoimmune Biosimilar Market With A Tuteur Deal
The deal for an undisclosed biosimilar with Argentina-based Tuteur gives Polpharma Biologics regional commercial coverage across most of Latin America.
Generics Bulletin - May 27, 2026
The deal for an undisclosed biosimilar with Argentina-based Tuteur gives Polpharma Biologics regional commercial coverage across most of Latin America.
Generics Bulletin - May 27, 2026
Daphne Koller’s Case For A Different Kind Of AI Biotech
The insitro founder and CEO has spent eight years proving that artificial intelligence can find what human intuition cannot. Now, with the clinic finally in sight, the hardest part is just beginning.
In Vivo - May 27, 2026
The insitro founder and CEO has spent eight years proving that artificial intelligence can find what human intuition cannot. Now, with the clinic finally in sight, the hardest part is just beginning.
In Vivo - May 27, 2026